The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: First in Human Study of AZD9592 in Solid Tumors
Official Title: A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors
Study ID: NCT05647122
Brief Summary: This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Duarte, California, United States
Research Site, Irvine, California, United States
Research Site, North Haven, Connecticut, United States
Research Site, Chicago, Illinois, United States
Research Site, Baltimore, Maryland, United States
Research Site, Milford, Massachusetts, United States
Research Site, Mineola, New York, United States
Research Site, New York, New York, United States
Research Site, New York, New York, United States
Research Site, New York, New York, United States
Research Site, Philadelphia, Pennsylvania, United States
Research Site, Providence, Rhode Island, United States
Research Site, Houston, Texas, United States
Research Site, Fairfax, Virginia, United States
Research Site, Kogarah, , Australia
Research Site, Melbourne, , Australia
Research Site, Edmonton, Alberta, Canada
Research Site, Toronto, Ontario, Canada
Research Site, Beijing, , China
Research Site, Beijing, , China
Research Site, Chongqing, , China
Research Site, Guangzhou, , China
Research Site, Harbin, , China
Research Site, Wuhan, , China
Research Site, Rennes, , France
Research Site, Villejuif Cedex, , France
Research Site, Milano, , Italy
Research Site, Orbassano, , Italy
Research Site, Rozzano, , Italy
Research Site, Verona, , Italy
Research Site, Chuo-ku, , Japan
Research Site, Kashiwa, , Japan
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Kuching, , Malaysia
Research Site, Barcelona, , Spain
Research Site, Madrid, , Spain
Research Site, Sevilla, , Spain
Research Site, Taichung, , Taiwan
Research Site, Taipei City, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taoyuan, , Taiwan
Name: Charu Aggarwal, MD, MPH
Affiliation: University of Pennsylvania
Role: PRINCIPAL_INVESTIGATOR